THE USE OF IMMUNOTHERAPY IN CHILDREN WITH RECURRENT BRONCHITIS

Recurrent bronchitis in childhood can lead to negative consequences in the form of sensitization and allergic diseases, including bronchial asthma. The aim: to research the clinical and immunological efficacy of broncho-vaxom in the group of children with recurrent bronchitis. Materials and methods: we examined 50 children with recurrent bronchitis (monthly) on the basis of allergo-immunological Department National Hospital No1 of Republik Sakha (Yakutskia). All children surveyed: general blood test and determination of the immune and cytokine status. 25 children received the drug, broncho-vaxom application of expectorants and mucolytic agents, another group (25 children) received only expectorants and mucolytic drugs. Results: in the analysis of changes of the immune status revealed the greatest decline in T-cell component and components of complement in children with recurrent bronchitis. In children with recurrent bronchitis increased levels of CIK, a reduced level of IFN-gamma FNO-alpha. 25 examined children with recurrent bronchitis medication used broncho-vaxom representing the lyophilisate of bacteria inhabiting the respiratory tract. The therapy was carried out ten-day course (1 capsule per day) for three months. In the analysis of changes of the immune status revealed an increased level of performance of T-cell (CD3+, CD4+, CD8+, CD16+) and immunoglobulins (IgA), the C4 component of compliment, as well as indicators of the level of blood cytokines (IL-1, FNO-alpha). Conclusions: as a result of drug therapy of broncho-vaxom marked improvement in immune status and the absence of recurrence of bronchitis for the next 3 months after the therapy.